Lanean...
Optimal use of lenvatinib in the treatment of advanced thyroid cancer
The development of orally active, multitargeted kinase inhibitors (MKIs) represents a significant advance in the treatment of progressive, metastatic thyroid cancer. Lenvatinib, an MKI targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet-derived growth f...
Gorde:
| Argitaratua izan da: | Cancers Head Neck |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6460646/ https://ncbi.nlm.nih.gov/pubmed/31093354 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s41199-017-0026-0 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|